The HER family of receptors has an important role in the network of cell si
gnals controlling cell growth and differentiation. Although the activity of
the HER receptor is strictly controlled in normal cells, HER2 receptor ove
rexpression plays a pivotal role in transformation and tumorigenesis. HER2
gene amplification and/or overexpression of the receptor has been detected
in subsets of a wide range of human cancers including breast cancer, and is
an indicator of poor prognosis. It is proposed that overexpressed HER2 in
combination with HER3 causes high activity of cell-signaling networks, ther
eby resulting in tumor cell proliferation. Thus, the HER2 receptor is an at
tractive target for new anti-cancer treatments. Monoclonal antibodies direc
ted against the receptor are the most promising of these, and the humanized
anti-HER2 monoclonal antibody trastuzumab (Herceptin) has shown significan
t clinical efficacy in clinical trials. The anti-tumor mechanisms of anti-H
ER2 monoclonal antibodies are not completely understood. However, some tumo
r types are not sensitive to trastuzumab, suggesting that the response of a
tumor to trastuzumab may not only be dependent on overexpressed HER2, but
may also be influenced by other members of the HER receptor family expresse
d in the tumor cell.